234 related articles for article (PubMed ID: 28066250)
1. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.
Franks LN; Ford BM; Prather PL
Front Pharmacol; 2016; 7():503. PubMed ID: 28066250
[TBL] [Abstract][Full Text] [Related]
2. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
3. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
5. CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2014 Jan; 443(1):144-9. PubMed ID: 24275139
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development.
Shoeib AM; Yarbrough AL; Ford BM; Franks LN; Urbaniak A; Hensley LL; Benson LN; Mu S; Radominska-Pandya A; Prather PL
Life Sci; 2021 Nov; 285():119993. PubMed ID: 34592231
[TBL] [Abstract][Full Text] [Related]
7. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
8. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre M; Smith CL
J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
11. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
14. Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death.
Shoeib AM; Benson LN; Mu S; MacMillan-Crow LA; Prather PL
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328467
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators in clinical practice: a safety overview.
Ellis AJ; Hendrick VM; Williams R; Komm BS
Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.
Osman NA; Ligresti A; Klein CD; Allarà M; Rabbito A; Di Marzo V; Abouzid KA; Abadi AH
Eur J Med Chem; 2016 Oct; 122():619-634. PubMed ID: 27448919
[TBL] [Abstract][Full Text] [Related]
19. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.
Crabtree JS; Peano BJ; Zhang X; Komm BS; Winneker RC; Harris HA
Mol Cell Endocrinol; 2008 Jun; 287(1-2):40-6. PubMed ID: 18367319
[TBL] [Abstract][Full Text] [Related]
20. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists.
Seely KA; Levi MS; Prather PL
J Pharmacol Exp Ther; 2009 Jul; 330(1):31-9. PubMed ID: 19359525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
